Skip to main content
. 2023 Nov 3;5(6):fcad296. doi: 10.1093/braincomms/fcad296

Table 3.

Demographic data and initial signs in patients with CBD–CBS, PSP–CBS and AD–CBS

Feature CBD–CBS (n = 16) PSP–CBS (n = 14) AD–CBS (n = 6) P-value, OR [(95% CI); CBD–CBS versus PSP–CBS] P-value, OR [(95% CI); CBD–CBS versus AD–CBS] P-value, OR [(95% CI); PSP–CBS versus AD–CBS]
Age at onset, years 63.5 ± 8.5 (45–79) 67.8 ± 6.3 (59–79) 69.5 ± 11.6 (55–86) 0.132 (−9.95 to 1.38) 0.196 (−3.36 to 15.36) 0.670 (−10.02 to 6.59)
Age at death, years 71.6 ± 8.7 (50–86) 75.9 ± 5.9 (68–88) 77.8 ± 12.0 (62–93) 0.131 (−9.97 to 1.36) 0.195 (−3.45 to 15.87) 0.724 (−14.52 to 10.71)
Duration of disease, years 8.4 ± 3.4 (4–17) 8.6 ± 3.6 (4–18) 8.5 ± 1.8 (7–11) 0.873 (−2.81 to 2.40) 0.966 (−2.98 to 3.10) 0.928 (−3.12 to 3.41)
Gait disturbance 13/15 (87) 10/14 (71) 5/6 (83) 0.390, 2.60 (0.39–17.16) 1.000, 1.30 (0.10–17.73) 1.000,0.50 (0.04–5.74)
 Slow gait 8/10 (80) 4/11 (36) 2/3 (67) 0.081, 7.00 (0.97–50.57) 1.000, 2.00 (0.11–34.82) 0.539, 0.29 (0.02–4.24)
 Unstable gait 7/11 (64) 7/12 (58) 2/5 (40) 1.000, 1.25 (0.23–6.71) 0.596, 2.63 (0.30–22.00) 0.620, 2.10 (0.25–17.59)
 Frozen gait 7/11 (64) 0/9 (0) 0/3 (0) 0.005*, 31.67 (1.46–685.34) 0.192, 11.67 (0.48–282.06) 1.000, 0.37 (0.01–22.39)
 Short steps gait 7/11 (64) 1/10 (10) 3/5 (60) 0.024*, 15.75 (1.42–174.25) 1.000, 1.17 (0.13–10.22) 0.077, 0.67 (0.00–1.14)
Bradykinesia 8/11 (73) 8/12 (67) 3/4 (75) 1.000, 1.33 (0.22–7.98) 1.000, 0.89 (0.06–12.25) 1.000,0.67 (0.05–8.64)
Clumsy limbs 8/13 (62) 10/14 (71) 4/6 (67) 0.695, 0.64 (0.13–3.20) 1.000, 0.80 (0.10–6.10) 1.000, 1.25 (0.16–9.77)
Falls 5/11 (45) 5/13 (38) 1/5 (20) 1.000, 1.33 (0.26–6.81) 0.588, 3.33 (0.28–40.29) 0.615, 2.50 (0.21–29.26)
Amnesia 4/13 (31) 4/14 (29) 3/6 (50) 1.000, 1.11 (0.21–5.80) 0.617, 0.44 (0.06–3.24) 0.613, 0.40 (0.06–2.89)
Tremor 6/15 (40) 0/14 (0) 2/6 (33) 0.017*, 19.84 (0.00–394.8) 1.000, 1.33 (0.18–9.73) 0.079, 0.06 (0.00–1.51)
Speech disturbance 5/12 (42) 7/13 (54) 2/5 (40) 0.695, 0.61 (0.13–2.98) 1.000, 1.07 (0.13–8.98) 1.000, 1.75 (0.22–14.22)
 Dysarthria 3/10 (30) 6/13 (46) 0/5 (0) 0.669, 0.50 (0.09–2.84) 0.506, 5.13 (0.22–121.11) 0.114, 9.53 (0.44–207.38)
 Aphasia 1/10 (10) 3/13 (23) 0/4 (0) 0.604, 0.37 (0.034.23) 1.000, 1.42 (0.05–42.22) 0.541, 3.00 (0.13–70.88)
Personality change 3/11 (27) 1/12 (8) 1/4 (25) 0.317, 4.13 (0.36–47.31) 1.000, 1.13 (0.08–15.51) 0.450, 0.27 (0.01–5.77)
Lack of insight 3/12 (25) 1/10 (10) 1/3 (33) 0.594, 3.00 (0.26–34.58) 1.000, 0.67 (0.04–10.25) 0.423, 0.22 (0.01–5.28)
Apraxia 3/11 (27) 6/12 (50) 4/5 (80) 0.400, 0.38 (0.07–2.14) 0.106, 0.09 (0.01–1.21) 0.338, 0.25 (002–2.94)
Behavioural change 1/13 (8) 1/12 (8) 0/5 (0) 1.000, 0.92 (0.05–16.50) 1.000, 1.32 (0.05–37.78) 1.000, 1.43 (0.05–41.23)
Irritability 1/13 (8) 2/11 (18) 1/4 (25) 0.576, 0.38 (0.03–4.81) 0.427, 0.25 (0.01–5.26) 1.000, 0.67 (0.04–10.25)

Data are presented as mean ± SD (range) or n (%). Bold number indicates statistical significance. AD, Alzheimer's disease; CBD, corticobasal degeneration; CBS, corticobasal syndrome; PSP, progressive supranuclear palsy [*P < 0.05 (t-test or Fisher’s exact test)]; OR, odds ratio; 95% CI, 95% confidence interval.